ATX-02

ATX-02 is a preclinical-stage therapeutic candidate being developed by ARTHEx Biotech for the treatment of muscular conditions and to promote muscle regeneration. Developed using ARTHEx's proprietary microRNA (miRNA) modulation platform, ATX-02 is designed as an antisense oligonucleotide (specifically an antagomir) that selectively targets microRNAs involved in muscle pathogenesis. While the specific miRNA target for ATX-02 has not been publicly disclosed, the program aims to address unmet needs in degenerative or wasting muscular disorders by leveraging the company's expertise in RNA therapeutics. ARTHEx Biotech, a spin-off from the University of Valencia, focuses on identifying miRNA modulators that can restore healthy gene expression patterns in neuromuscular diseases.